Published January 13, 2025 | Version v1
Journal article Open

Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer

  • 1. University of Chicago
  • 2. Sheba Medical Center
  • 3. East China University of Science & Technology
  • 4. University of California, Irvine

Description

Metabolic reprogramming of tumor cells is an emerging hallmark of cancer. Among all the changes in cancer metabolism, increased glucose uptake and the accumulation of lactate under normoxic conditions (the "Warburg effect") is a common feature of cancer cells. In this study, we develop a lactate-responsive drug delivery platform by targeting the Warburg effect. We design and test a gold/mesoporous silica Janus nanoparticle system as a gated drug carrier, in which the gold particles are functionalized with lactate oxidase and the silica particles are capped with α-cyclodextrin through surface arylboronate modification. In the presence of lactate, the lactate oxidase generates hydrogen peroxide, which induces the self-immolation reaction of arylboronate, leading to uncapping and drug release. Our results demonstrate greatly improved drug delivery specificity and therapeutic efficacy with this platform for the treatment of different cancers. Our findings present an effective approach for drug delivery by metabolic targeting of tumors.

Data availability

scRNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table. Microscopy data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Files

Enabling-tumor-specific-drug-delivery-by-targeting-the-Warburg-effect-of-cancer.pdf

Files (20.2 MB)

Name Size Download all
Article
md5:16c6491b9b1416bc4878c627a8935c03
6.2 MB Preview Download
Supplemental information files
md5:a12949e9f4fbd158dc576fca965f5467
13.9 MB Preview Download

Additional details

Identifiers

DOI
10.1016/j.xcrm.2024.101920
Other
oai:uchicago.tind.io:14409

Funding

National Institutes of Health
R01OD023700
National Institutes of Health
R21AR080761
National Institutes of Health
R01DA047785
National Institutes of Health
R01AR78555
University of Chicago
Technology Impact Award
Samuel Waxman Cancer Research Foundation
Alan B. Slifka Foundation
Israel Cancer Fund
Pediatric Sarcoma Grant
Rally Foundation
Outside the Box Grant
University of Chicago Medicine Comprehensive Cancer Center
Duckworth Family Commercial Promise Award
Unknown funder
Cancer Immunotherapy Team Science Award
Unknown funder
Pancreatic Cancer SPORE grant
Unknown funder
UCHAP pilot award
Unknown funder
Ullman Family Team Science Award
Unknown funder
1DP2AI144245

UChicago Information

Division(s)
Biological Sciences Division, Pritzker School of Molecular Engineering
Department(s)
Ben May Department for Cancer Research